Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207305 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
A Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06207305: Recruiting Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel, sponsored by M.D. Anderson Cancer Center.
NCT06207305 is a Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06207305, a Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Dexamethasone
- DRUG Diphenhydramine
- DRUG Famotidine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2028-01-02 |
| Phase | Phase 1 |
What NCT06207305 shows while recruiting
NCT06207305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Metastatic Appendiceal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Paclitaxel is the first listed.
NCT06207305 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06207305 about?
NCT06207305 is a clinical study titled "A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma". To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
What is the current status of trial NCT06207305?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2024-01-30. Estimated completion is 2028-01-02.
What conditions does trial NCT06207305 study?
This clinical trial studies the following conditions: Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel.
What interventions are being tested in trial NCT06207305?
The interventions under investigation include: Paclitaxel (DRUG), Dexamethasone (DRUG), Diphenhydramine (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT06207305?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06207305 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06207305's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI